Search | HMA-EMA Catalogues of real-world data sources and studies

Population Health Data Center (PHDc), National Cheng Kung University (NCKU)

Taiwan

First published:

20/10/2025

Last updated 03/11/2025

Institution Educational Institution

The Danish Multiple Sclerosis Registry

First published:

03/11/2025

Last updated 03/11/2025

Denmark

Data source

Human

Disease registry

INvestigating SIGnificant Health TrendS in Growth Hormone Treatments Registry

First published:

13/05/2024

Last updated 03/11/2025

Germany

Data source

Human

Disease registry

Study protocol objective 2_feasibility assessement: Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks (TARGET-EU-FA)

Belgium

Denmark

Finland

Greece

Italy

Netherlands

Norway

Spain

United Kingdom

EU PAS number:

EUPAS1000000791

First published:

31/10/2025

Last updated 31/10/2025

Study Finalised

An observational study evaluating long-acting injectable cabotegravir (CAB-LA; APRETUDE) healthcare provider and user experience and utilization for pre-exposure prophylaxis (PrEP) against HIV in Canada (223857)

Canada

EU PAS number:

EUPAS1000000801

First published:

31/10/2025

Last updated 31/10/2025

Study Planned

Lifetime prevalence of Type 2 comorbidities in patients with COPD: especially those with higher eosinophilic counts

United Kingdom

EU PAS number:

EUPAS1000000792

First published:

31/10/2025

Last updated 31/10/2025

Study Planned

Prospective, virtual, real-world data study in adults and adolescents ≥12 years with symptoms suggestive of acute rhinosinusitis (SinARv)

Germany

EU PAS number:

EUPAS1000000526

First published:

27/03/2025

Last updated 31/10/2025

Study Finalised

DARWIN EU® -Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products

Croatia

Denmark

Germany

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS1000000403

First published:

03/12/2024

Last updated 31/10/2025

Study Finalised

An Observational Registry-Based Study to Evaluate the Long-Term Safety of Tofersen in People With SOD1-ALS

Belgium

Ireland

Switzerland

United States

EU PAS number:

EUPAS1000000365

First published:

31/10/2025

Last updated 31/10/2025

Study Planned

Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)

Finland

Sweden

United Kingdom

EU PAS number:

EUPAS16424

First published:

16/12/2016

Last updated 31/10/2025

Study Finalised

Alofisel-4001: Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula

Austria

Czechia

France

Germany

Israel

Spain

EU PAS number:

EUPAS31439

First published:

07/10/2019

Last updated 31/10/2025

Study Finalised

The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)

Spain

First published:

01/02/2024

Last updated 31/10/2025

Institution

Pharmaceutical Policy - research group, University of Eastern Finland

Finland

First published:

30/10/2025

Last updated 30/10/2025

Institution Educational Institution ENCePP partner

CABOLIFE: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients with Neuroendocrine Tumours

Austria

Germany

EU PAS number:

EUPAS1000000752

First published:

30/10/2025

Last updated 30/10/2025

Study Planned

Phenotyping Asthma Exacerbations in primary care: an electronic medical record study (PHASE)

United Kingdom

EU PAS number:

EUPAS1000000566

First published:

06/05/2025

Last updated 30/10/2025

Study Ongoing

Evaluation of the effectiveness of additional risk minimisation measures (aRMMs) that aim to reduce the risks of phototoxicity, squamous cell carcinoma (SCC) of the skin and hepatic toxicity in patients receiving voriconazole in Saudi Arabia

Saudi Arabia

EU PAS number:

EUPAS1000000266

First published:

30/10/2024

Last updated 30/10/2025

Study Finalised

Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)

United States

EU PAS number:

EUPAS1000000229

First published:

10/09/2024

Last updated 30/10/2025

Study Planned

A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)

Italy

Netherlands

Spain

United Kingdom

EU PAS number:

EUPAS43556

First published:

07/10/2021

Last updated 30/10/2025

Study Finalised

Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

Italy

Netherlands

Norway

Spain

United Kingdom

EU PAS number:

EUPAS47708

First published:

22/08/2022

Last updated 30/10/2025

Study Finalised

Survey among healthcare professionals (neurologists treating patients with MS along with MS specialist nurses) and patients in selected European countries plus Canada to evaluate the knowledge required for the safe use of Mayzent (siponimod)

Canada

Croatia

Denmark

Germany

Netherlands

Spain

Sweden

EU PAS number:

EUPAS44782

First published:

22/12/2021

Last updated 30/10/2025

Study Ongoing

Real-world Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients (Brentuximab-5020)

France

Germany

Spain

EU PAS number:

EUPAS104804

First published:

24/05/2023

Last updated 30/10/2025

Study Finalised

Frequency of HIV diagnoses among people using oral and LA PrEP

United States

EU PAS number:

EUPAS1000000371

First published:

21/11/2024

Last updated 30/10/2025

Study Ongoing

A post-authorisation safety study (PASS) to describe real-world safety and effectiveness of NUCALA (mepolizumab) in paediatric eosinophilic granulomatosis with polyangiitis (EGPA) patients in Europe (218065)

France

Germany

Italy

Spain

United Kingdom

EU PAS number:

EUPAS49460

First published:

03/11/2022

Last updated 30/10/2025

Study Ongoing

Real World Utilization and Effectiveness of Romosozumab Among Osteoporosis Patients in Hong Kong (20250006)

China

EU PAS number:

EUPAS1000000724

First published:

05/09/2025

Last updated 30/10/2025

Study Planned

CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study

Denmark

France

Germany

Italy

Norway

Spain

Sweden

United Kingdom

EU PAS number:

EUPAS39438

First published:

10/02/2021

Last updated 30/10/2025

Study Ongoing

Long Term Post Marketing Drug Use Result Survey for Blinatumomab in Japan (20180238) (Blinatumomab Long Term PMS Japan)

Japan

EU PAS number:

EUPAS29685

First published:

09/05/2019

Last updated 30/10/2025

Study Finalised

EAU UroEvidenceHub (UEH)

Denmark

Germany

Greece

Italy

Netherlands

Poland

Portugal

Spain

United Kingdom

First published:

24/10/2025

Last updated 30/10/2025

Network

Data Integration Center (DIZ), Medical University Lausitz - Carl Thiem

Germany

First published:

30/10/2025

Last updated 30/10/2025

Institution Hospital/Clinic/Other health care facility

The Danish Multiple Sclerosis Registry (DMSR), Rigshospitalet - Copenhagen University Hospital

Denmark

First published:

23/10/2025

Last updated 30/10/2025

Institution Educational Institution Hospital/Clinic/Other health care facility

Vedolizumab-4018: Observational Study of the Effectiveness of Vedolizumab on Treatment Outcomes and HRQoL in biologic naïve Patients with Inflammatory Bowel Diseases in Greece (TROVE)

Greece

EU PAS number:

EUPAS23580

First published:

11/05/2018

Last updated 30/10/2025

Study Finalised

Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)

France

Germany

EU PAS number:

EUPAS1000000776

First published:

24/10/2025

Last updated 24/10/2025

Study Planned

An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS)

Denmark

France

Germany

United States

EU PAS number:

EUPAS1000000169

First published:

24/05/2024

Last updated 24/10/2025

Study Planned

INOtuzumab Treatment Retrospective Analysis for Navigating tranSITion to CD19 CAR-T. Real-world (RWD) treatment patterns and clinical outcomes in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) treated with inotuzumab-ozogamicin (InO) as bridge to chimeric antigen receptor T-cell (CAR-T) therapy in Spain, the United Kingdom (UK) and the United States (US) (INO-TRANSIT)

Spain

United Kingdom

United States

EU PAS number:

EUPAS1000000118

First published:

24/05/2024

Last updated 24/10/2025

Study Ongoing

National Health Insurance Research Database

First published:

23/10/2025

Last updated 24/10/2025

Taiwan

Data source

Human

Administrative healthcare records (e.g., claims)

German Atopic Dermatitis Registry TREATgermany

First published:

01/02/2024

Last updated 23/10/2025

Germany

Data source

Human

Disease registry Primary care medical records

DARWIN EU® – Drug Utilisation Study of terbinafine-containing products

Croatia

Denmark

Finland

Germany

Spain

United Kingdom

EU PAS number:

EUPAS1000000790

First published:

23/10/2025

Last updated 23/10/2025

Study Ongoing

Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT)

Argentina

Belgium

Brazil

Bulgaria

Canada

Colombia

Denmark

Estonia

Greece

India

Ireland

Italy

Japan

Korea, Republic of

Kuwait

Mexico

Norway

Poland

Portugal

Saudi Arabia

Singapore

Spain

Taiwan

United Arab Emirates

United Kingdom

United States

EU PAS number:

EUPAS1000000789

First published:

23/10/2025

Last updated 23/10/2025

Study Ongoing

Sustainability of response to biologics in severe asthma and predictors of late failure among patients in an international registry (SHINE)

Argentina

Belgium

Brazil

Bulgaria

Canada

Colombia

Denmark

Estonia

Greece

Ireland

Italy

Japan

Korea, Republic of

Kuwait

Mexico

Norway

Poland

Portugal

Saudi Arabia

Singapore

Spain

Taiwan

United Arab Emirates

United Kingdom

United States

EU PAS number:

EUPAS1000000788

First published:

23/10/2025

Last updated 23/10/2025

Study Ongoing

A Non-interventional Real-World Study on Dose Modifications of Enfortumab Vedotin (EV) in Combination with Pembrolizumab (P) in Previously Untreated Patients with Advanced Urothelial Carcinoma in Germany

Germany

EU PAS number:

EUPAS1000000467

First published:

21/02/2025

Last updated 23/10/2025

Study Discontinued

Treatment and Clinical Characteristics in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) using Talazoparib and Enzalutamide (tala+enza) Combination Therapy

United States

EU PAS number:

EUPAS1000000580

First published:

01/08/2025

Last updated 23/10/2025

Study Ongoing

Search all content

Results(4467)